BrightKaire Featured in The Times of Israel: Israeli-Developed Blood Test Promises to Take Guesswork out of Treating Depression

For decades, treating depression has relied largely on trial and error, with many patients spending months or even years searching for an effective medication. In this feature, The Times of Israel examines how NeuroKaire is working to change that reality with BrightKaire™, the first clinically deployed test based on neurons derived from a patient’s blood.

The article explores how NeuroKaire’s proprietary “brain-in-a-dish” platform combines stem cell technology, genomics, and artificial intelligence to predict how an individual will respond to antidepressant medications before treatment begins. By generating patient-specific neurons and analyzing their responses to multiple therapies, BrightKaire aims to provide clinicians with personalized treatment insights and significantly reduce the time required to find an effective antidepressant.

The coverage highlights NeuroKaire’s broader mission to bring precision medicine to mental health care and underscores the growing potential of biologically informed tools to improve outcomes for patients living with major depressive disorder.

👉 Read the full article

‍